Intellia Therapeutics Statistics
Share Statistics
Intellia Therapeutics has 101.85M shares outstanding. The number of shares has increased by 13.43% in one year.
| Shares Outstanding | 101.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 5.29% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 100.10M |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 16.15M, so 15.86% of the outstanding shares have been sold short.
| Short Interest | 16.15M |
| Short % of Shares Out | 15.86% |
| Short % of Float | 16.14% |
| Short Ratio (days to cover) | 6.23 |
Valuation Ratios
The PE ratio is -5.62 and the forward PE ratio is -3.02.
| PE Ratio | -5.62 |
| Forward PE | -3.02 |
| PS Ratio | 74.61 |
| Forward PS | 21.9 |
| PB Ratio | 2.58 |
| P/FCF Ratio | -6.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Intellia Therapeutics Inc. has an Enterprise Value (EV) of 2.60B.
| EV / Earnings | -5.39 |
| EV / Sales | 71.54 |
| EV / EBITDA | -5.13 |
| EV / EBIT | -5.04 |
| EV / FCF | -6.36 |
Financial Position
The company has a current ratio of 8.67, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.67 |
| Quick Ratio | 8.67 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.74 |
| Cash Flow / Debt | -21.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -44.21%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -44.21% |
| Revenue Per Employee | 68.96K |
| Profits Per Employee | -914.81K |
| Employee Count | 526 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.12% in the last 52 weeks. The beta is 1.81, so Intellia Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.81 |
| 52-Week Price Change | -58.12% |
| 50-Day Moving Average | 16.28 |
| 200-Day Moving Average | 22.16 |
| Relative Strength Index (RSI) | 38.97 |
| Average Volume (20 Days) | 2.44M |
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of $36.27M and earned -$481.19M in profits. Earnings per share was $-5.42.
| Revenue | 36.27M |
| Gross Profit | 27.30M |
| Operating Income | -515.29M |
| Net Income | -481.19M |
| EBITDA | -506.31M |
| EBIT | -515.29M |
| Earnings Per Share (EPS) | -5.42 |
Balance Sheet
The company has $226.75M in cash and $115.35M in debt, giving a net cash position of $111.40M.
| Cash & Cash Equivalents | 226.75M |
| Total Debt | 115.35M |
| Net Cash | 111.40M |
| Retained Earnings | -1.66B |
| Total Assets | 1.17B |
| Working Capital | 605.22M |
Cash Flow
In the last 12 months, operating cash flow was -$394.09M and capital expenditures -$13.98M, giving a free cash flow of -$408.07M.
| Operating Cash Flow | -394.09M |
| Capital Expenditures | -13.98M |
| Free Cash Flow | -408.07M |
| FCF Per Share | -4.6 |
Margins
Gross margin is 75.26%, with operating and profit margins of -1.42K% and -1.33K%.
| Gross Margin | 75.26% |
| Operating Margin | -1.42K% |
| Pretax Margin | -1.33K% |
| Profit Margin | -1.33K% |
| EBITDA Margin | -1.40K% |
| EBIT Margin | -1.42K% |
| FCF Margin | -1.12K% |
Dividends & Yields
NTLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -42.05% |
| FCF Yield | -31.07% |
Analyst Forecast
The average price target for NTLA is $57.5, which is 346.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $57.5 |
| Price Target Difference | 346.1% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Scores
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 2 |